Biogen takes global felzartamab rights in TJ Bio China deal
Bottom line
Biogen is consolidating global control of felzartamab, agreeing to acquire TJ Biopharma’s exclusive Greater China rights to the investigational anti-CD38 antibody in a deal worth up to about $850 million. The companies said TJ Bio will receive $100 million upfront, with up to $750 million tied to commercial and sales milestones, plus royalties on Greater China sales. The April 20 agreement gives Biogen worldwide development and commercialization rights to felzartamab, which it had already controlled outside Greater China after acquiring HI-Bio in July 2024. Felzartamab is now in Phase 3 development for antibody-mediated rejection in kidney transplant recipients, IgA nephropathy, and primary membranous nephropathy. (investors.biogen.com)
Why it matters: While this is a human biopharma deal, it’s notable for veterinary professionals because it underscores continued investment in antibody-based immunology platforms, especially therapies targeting plasma cells and antibody-driven disease. Those mechanisms have growing relevance across translational medicine, including immune-mediated conditions that veterinarians watch closely in companion animals. The deal also shows how companies are seeking cleaner global rights structures to streamline late-stage development, regulatory strategy, manufacturing, and future commercialization. (investors.biogen.com)
What to watch: Next steps include progress in Biogen’s Phase 3 kidney disease programs, any regulatory movement in China, and whether felzartamab’s anti-CD38 approach expands into additional immune-mediated indications. (investors.biogen.com)
Biogen has struck a deal to take full worldwide control of felzartamab, licensing TJ Biopharma’s Greater China rights to the investigational anti-CD38 antibody in a transaction worth up to roughly $850 million. Announced April 20, the agreement includes $100 million upfront, as much as $750 million in milestone payments, and royalties on sales in Greater China. With the transaction, Biogen says it now holds exclusive worldwide development and commercialization rights to the asset. (investors.biogen.com)
The move builds on Biogen’s July 2024 acquisition of HI-Bio, which brought in worldwide rights to felzartamab except for Greater China. That left a geographic gap in a program Biogen has been positioning as a potentially broad immunology franchise. In April 2025, TJ Bio joined Biogen-sponsored Phase 3 multi-regional studies in China for IgA nephropathy and primary membranous nephropathy, formalizing the companies’ operational and regulatory collaboration there. (investors.biogen.com)
Felzartamab is an investigational monoclonal antibody directed against CD38 on mature plasma cells. Biogen is advancing it in Phase 3 programs for antibody-mediated rejection in kidney transplant recipients, IgA nephropathy, and primary membranous nephropathy, and has also pointed to possible future expansion into other immune-mediated diseases, including lupus nephritis. The scientific rationale is that selectively depleting CD38-positive plasma cells could reduce pathogenic antibodies while opening a broader set of autoimmune and nephrology uses. (investors.biogen.com)
There’s also a China regulatory piece that adds context. TJ Bio said in April 2025 that it had already submitted a biologics license application to China’s National Medical Products Administration in December 2024 for felzartamab in multiple myeloma, and that filing had been accepted for review. Reuters reported that under the new arrangement, Biogen would lead manufacturing and commercial efforts in Greater China if the drug is approved there, while TJ Bio would continue manufacturing for the multiple myeloma use at its Hangzhou facility. (tjbio.com)
Company commentary around the deal was focused on scale and portfolio logic. Biogen’s Fraser Hall said the agreement expands the “global opportunity” for felzartamab, while company materials have repeatedly described the drug as a potential “pipeline-in-a-product.” That framing suggests Biogen sees value not just in the current kidney disease studies, but in owning a cleaner global rights package that could support broader lifecycle planning, partnering, and market access decisions. (investors.biogen.com)
Why it matters: For veterinary professionals, this isn’t a practice-changing animal health development, but it is a useful signal from the broader biologics market. Large deals continue to cluster around targeted immunology assets with platform potential, especially drugs aimed at antibody-mediated disease. That matters because veterinary medicine increasingly tracks human innovation in monoclonal antibodies, immune modulation, manufacturing strategy, and regulatory pathways. It also reinforces how companies value simplified territorial rights as programs move into late-stage trials and possible commercialization. (investors.biogen.com)
What to watch: The near-term milestones are clinical and regulatory: enrollment and readouts from Biogen’s Phase 3 renal programs, any updates on China review activity, and signs that Biogen will push felzartamab into additional indications beyond kidney disease and transplant rejection. If those programs generate strong data, this deal will look less like a regional clean-up and more like a strategic bet on a broader immunology franchise. (investors.biogen.com)